SCHEMBL13005454

SCHEMBL13005454

CC(C)Cc1cccc(-c2cccc(C(=O)NCCN3CCCCC3)c2)c1

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 1/20 0.60
SMYD2 Q9NRG4 2/20 0.54
APP P05067 1/20 0.52
CACNA1G O43497 4/20 0.51
MAP4K4 O95819 1/20 0.50
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
ATR Q13535 1/20 0.49
PARP1 P09874 1/20 0.49
EPHX2 P34913 1/20 0.49
HPGD P15428 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
CYP1A2 P05177 1/20 0.49
CYP2D6 P10635 1/20 0.49
CYP2C9 P11712 1/20 0.49
CAMK2D Q13557 1/20 0.49
IKBKB O14920 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13005453 0.99 ERN1 (0.59) ERN1SMYD2APPCACNA1GMAP4K4
SCHEMBL13005466 0.94 SMYD2 (0.63) ERN1SMYD2MEN1KMT2APARP1
SCHEMBL13005469 0.91 CHRM3 (0.54) ERN1SMYD2PARP1CYP2C9
SCHEMBL13061007 0.88 ERN1 (0.64) ERN1SMYD2APPCACNA1GMAP4K4
SCHEMBL13060642 0.86 ERN1 (0.62) ERN1SMYD2APPCACNA1GMAP4K4
SCHEMBL13005547 0.82 TACR2 (0.42) ERN1SMYD2
SCHEMBL13060850 0.81 SMYD2 (0.67) ERN1SMYD2MEN1KMT2APARP1
SCHEMBL8252160 0.81 NPSR1 (0.65) CACNA1GMEN1KMT2AHPGDNPSR1
SCHEMBL774938 0.81 ERN1 (0.70) ERN1SMYD2APPCACNA1GMAP4K4
SCHEMBL13675357 0.80 PARP1 (0.58) ERN1CACNA1GMEN1KMT2APARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851637-B2 Compounds and methods for inhibiting the interaction of BCL proteins with binding partners INFINITY PHARMACEUTICALS, INC. (US) 2010-12-14 US disclosed
US-7851637-B2 Compounds and methods for inhibiting the interaction of BCL proteins with binding partners INFINITY PHARMACEUTICALS, INC. (US) 2010-12-14 US disclosed